Clinical Trial Update: Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 dosing study evaluating radiation in combination with tislelizumab and pamiparib in previously treated head and neck cancer is currently recruiting at t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pamiparib (pamiparib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING